Discovery of adjunctive agents for use with hormone deprivation therapy in breast cancer with tamoxifen, letrozole, anastrozole or exemestane.
Abstract
These agents are different from those that target kinases specifically expressed in the HR+ molecular subtypes. Kinases activated by exposure to tamoxifen in human cells included MAP3K6 and STK40.
Fields of Study & Subjects
Estrogen and related hormone effects
Breast Cancer Treatment Studies
Advanced Breast Cancer Therapies
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 15 February 2026
- Language
- EN
- Document type
- Preprint